课题基金 / 基金详情

Profiling circulating DNA and RNA to identify mechanisms of therapeutic resistance and response in metastatic castration-resistant prostate cancer

Profiling circulating DNA and RNA to identify mechanisms of therapeutic resistance and response in metastatic castration-resistant prostate cancer
分析循环 DNA 和 RNA,以确定转移性去势抵抗性前列腺癌的治疗抵抗和反应机制
批准号:
nhmrc : 1098647
负责人:
A/Pr Arun Azad
金额:
$33.18万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2016
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2016-01-01 至 2019-12-31

项目摘要

项目成果

A/Pr Arun Azad的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel targeting of therapy-resistant prostate cancer cells.
  • 批准号:
    nhmrc : 1140222
  • 项目类别:
    Project Grants
  • 资助金额:
    $40.36万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Arun Azad
  • 依托单位:
A novel strategy for targeting castrate-resistant prostate cancer
  • 批准号:
    nhmrc : 1138242
  • 项目类别:
    Project Grants
  • 资助金额:
    $54.05万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Arun Azad
  • 依托单位:
Novel targeting of therapy-resistant prostate cancer cells.
  • 批准号:
    nhmrc : GNT1140222
  • 项目类别:
    Project Grants
  • 资助金额:
    $59.7万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Arun Azad
  • 依托单位:
A novel strategy for targeting castrate-resistant prostate cancer
  • 批准号:
    nhmrc : GNT1138242
  • 项目类别:
    Project Grants
  • 资助金额:
    $79.94万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Arun Azad
  • 依托单位:
国内基金
海外基金
基于量子点多色荧光细胞标志谱型的CTC鉴别与肿瘤个体化诊治的研究
  • 批准号:
    30772507
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2007
  • 负责人:
    赵晓航
  • 依托单位: